LivaNova (NASDAQ:LIVN) was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a note issued to investors on Thursday.

A number of other brokerages have also commented on LIVN. Stifel Nicolaus boosted their target price on LivaNova from $135.00 to $140.00 and gave the company a “buy” rating in a research report on Monday, September 17th. Needham & Company LLC reaffirmed a “buy” rating and issued a $135.00 target price (up from $128.00) on shares of LivaNova in a research report on Wednesday, August 1st. Jefferies Financial Group boosted their target price on LivaNova to $150.00 and gave the company a “buy” rating in a research report on Tuesday, October 2nd. Zacks Investment Research lowered LivaNova from a “buy” rating to a “hold” rating in a research report on Thursday, September 20th. Finally, BTIG Research reaffirmed a “hold” rating on shares of LivaNova in a research report on Thursday, November 1st. Three equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $126.50.

Shares of LivaNova stock opened at $98.26 on Thursday. LivaNova has a one year low of $76.14 and a one year high of $131.54. The stock has a market capitalization of $5.85 billion, a P/E ratio of 29.69, a PEG ratio of 3.61 and a beta of 0.94. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.65 and a quick ratio of 1.21.

LivaNova (NASDAQ:LIVN) last issued its earnings results on Wednesday, October 31st. The company reported $0.82 EPS for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.08). LivaNova had a negative net margin of 8.31% and a positive return on equity of 8.77%. The firm had revenue of $272.10 million during the quarter, compared to the consensus estimate of $275.03 million. During the same period in the previous year, the firm earned $0.83 earnings per share. The business’s quarterly revenue was up 8.3% on a year-over-year basis. Analysts expect that LivaNova will post 3.1 EPS for the current fiscal year.

In other LivaNova news, Director Daniel Jeffrey Moore sold 1,000 shares of the business’s stock in a transaction that occurred on Monday, September 17th. The stock was sold at an average price of $123.49, for a total transaction of $123,490.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider David S. Wise sold 1,500 shares of the business’s stock in a transaction that occurred on Monday, September 17th. The stock was sold at an average price of $123.43, for a total value of $185,145.00. The disclosure for this sale can be found here. Insiders have sold a total of 8,500 shares of company stock valued at $1,002,355 over the last three months. Corporate insiders own 0.41% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of LIVN. UBS Group AG increased its holdings in LivaNova by 47.8% during the 1st quarter. UBS Group AG now owns 14,477 shares of the company’s stock worth $1,281,000 after purchasing an additional 4,683 shares in the last quarter. Royal Bank of Canada increased its holdings in LivaNova by 1,050.6% during the 1st quarter. Royal Bank of Canada now owns 7,168 shares of the company’s stock worth $634,000 after purchasing an additional 6,545 shares in the last quarter. Principal Financial Group Inc. increased its holdings in LivaNova by 3.0% during the 1st quarter. Principal Financial Group Inc. now owns 191,925 shares of the company’s stock worth $16,985,000 after purchasing an additional 5,532 shares in the last quarter. Bank of Montreal Can increased its holdings in LivaNova by 15.2% during the 2nd quarter. Bank of Montreal Can now owns 4,411 shares of the company’s stock worth $441,000 after purchasing an additional 582 shares in the last quarter. Finally, Amalgamated Bank increased its holdings in LivaNova by 12.8% during the 2nd quarter. Amalgamated Bank now owns 7,717 shares of the company’s stock worth $770,000 after purchasing an additional 876 shares in the last quarter. 82.26% of the stock is owned by hedge funds and other institutional investors.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves.

See Also: How are the companies in the S&P 500 selected?

Analyst Recommendations for LivaNova (NASDAQ:LIVN)

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.